Oncology – Urological
Opinion | Low-grade prostate cancer (Gleason score 6): time to stop calling it cancer.
19 Apr, 2022 | 02:29h | UTCLow-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Commentary: Doctors suggest new names for low-grade prostate cancer – Associated Press
10-year results of a phase 3 RCT: High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer.
19 Apr, 2022 | 01:22h | UTCHigh-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology (link to abstract – $ for full-text)
Endocrine therapies for breast and prostate cancers: Essentials for primary care.
19 Apr, 2022 | 01:14h | UTC
Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with hematuria.
14 Apr, 2022 | 08:16h | UTCSystematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuriahttps://t.co/zB6CHYKprL@stingrai78 @drimranomar @ahmostafid @soukup_viktor @Phil_Violette pic.twitter.com/Ouv3lFfRpm
— European Urology (@EUplatinum) April 11, 2022
Cohort Study: Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer.
14 Apr, 2022 | 07:59h | UTCCommentary: Men treated for prostate cancer have increased fracture risk, yet few complete DXA screening – HealthImaging
Commentary on Twitter
In this cohort study, osteoporosis screening rates for over 50,000 elderly men with prostate cancer receiving hormonal therapy nationwide were very low; men who were screened were less likely to suffer major fractures in follow-up. https://t.co/RMz1bvEgiA
— JAMA Network Open (@JAMANetworkOpen) April 1, 2022
RCT: Effects of abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer.
11 Apr, 2022 | 01:23h | UTCAbiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design – The Lancet (link to abstract – $ for full-text)
Systematic Review: Diagnostic and prognostic factors in patients with prostate cancer.
7 Apr, 2022 | 08:16h | UTCDiagnostic and prognostic factors in patients with prostate cancer: a systematic review – BMJ Open
Canadian recommendations on prostate cancer screening and early diagnosis.
6 Apr, 2022 | 09:47h | UTCSee also: Summary of changes
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer.
1 Apr, 2022 | 08:30h | UTC
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer.
31 Mar, 2022 | 07:46h | UTC
EAU Guidelines on renal cell carcinoma.
30 Mar, 2022 | 10:19h | UTC
German guidelines for diagnostics and prognostic evaluation in renal cell tumors.
25 Mar, 2022 | 08:25h | UTC
Current management of urachal carcinoma: an evidence-based guide for clinical practice.
22 Mar, 2022 | 08:09h | UTC
RCT: Imaging modality (CT vs. MRI) and frequency (seven scans over 60 months vs. three scans over 36 months) in surveillance of Stage I Seminoma Testicular Cancer.
21 Mar, 2022 | 08:39h | UTCImaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Summary: German evidence-based guidelines on focal therapy in localized prostate cancer.
17 Mar, 2022 | 08:47h | UTC
Cohort Study: adjuvant vs. early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer.
17 Mar, 2022 | 08:09h | UTC
RCT: Observation vs. screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases.
16 Mar, 2022 | 08:26h | UTC
Commentary on Twitter
In @LancetOncology : Brilliant question answered by this RCT?Any role of screening for malignant spinal cord compression & pre-emptive Rx in asymptomatic mCRPC #prostatecancer ? Answer is "NO". Congrats to @DearnaleyProf & team Free access: https://t.co/8r4yJOYCLA @OncoAlert pic.twitter.com/8oLIwKKOx1
— Neeraj Agarwal (@neerajaiims) March 12, 2022
M-A: Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy.
15 Mar, 2022 | 08:05h | UTC
RCT: Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer.
14 Mar, 2022 | 00:41h | UTC
GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer.
10 Mar, 2022 | 10:35h | UTC
RCT: Pain and health-related quality of life with olaparib vs. physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.
10 Mar, 2022 | 10:18h | UTCPain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Review: Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer.
10 Mar, 2022 | 10:02h | UTC
Multiparametric ultrasound vs. multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
7 Mar, 2022 | 00:04h | UTCMultiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study – The Lancet Oncology (link to abstract – $ for full-text)
News Release: Ultrasound scan can diagnose prostate cancer – Imperial College London
Commentary on Twitter
In a prospective confirmatory study comparing multiparametric US vs MRI for prostate cancer detection in 306 men with an abnormal PSA or DRE findings, US detected 4.3% fewer clinically significant cancers despite 11.1% more pts being referred for a biopsy: https://t.co/ZFkiUTFJ5Y
— NatureRevClinOncol (@NatRevClinOncol) March 3, 2022
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
(Epi)genetic predisposing factors found in one-third of children diagnosed with Wilms tumor.
3 Mar, 2022 | 08:10h | UTC